Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Stem Cell Therapeutics Provides Corporate Update

Published: Monday, January 20, 2014
Last Updated: Monday, January 20, 2014
Bookmark and Share
Company provides six-month corporate update.

Stem Cell Therapeutics Corp. has provided the following six-month corporate update:

• Pilot non-human primate tolerability studies have been completed using SIRPaFc, Stem Cell Therapeutics’ proprietary CD47 antagonist. Three separate human SIRPaFc proteins, possessing different Fc regions with varying levels of effector function, were evaluated in a repeat-dose regimen in cynomolgus macaques. Safe dosing levels, substantially above the anticipated human therapeutic dose, were established for each drug candidate. Greater tolerability was observed to correlate with decreasing effector function. Anemia and thrombocytopenia were the primary adverse events observed, which in most cases were asymptomatic and reversible.

These studies, while preliminary in nature, provided firm support for moving the SIRPaFc program forward into the next development phase. In parallel with conducting the manufacturing activities and toxicology studies typically associated with the IND-enabling phase of drug development, the company will significantly amplify its preclinical efficacy studies. This will be critical in order to uncover the full potential of this promising immune checkpoint inhibitor and to expand its use in the treatment of both solid and liquid tumors.

• Preclinical SIRPaFc efficacy data in an acute myeloid leukemia xenograft model was recently reported at the 55th Annual Meeting of the American Society of Hematology (ASH). SIRPaFc was shown to promote potent anti-leukemic responses at low doses. When combined with the non-human primate tolerability data, this indicates a wide therapeutic window. For details on the ASH presentation please consult our website at www.stemcellthera.com.

• On December 13, 2013, the company completed a $33 million private placement, principally with participation from experienced U.S. healthcare institutional investors. Importantly, this substantial financing, one of the largest by a Canadian biopharmaceutical company last year, was primarily driven by the strength and promise of the SIRPaFc technology. Its proceeds will allow the company to execute an optimal development program over the next three years, which will include manufacturing, formal toxicology testing, as well as clinical studies in cancer patients.

• Dosing in the investigator-driven Phase I multicenter dose-escalation study (50mg-350mg) with tigecycline in patients with relapsed or refractory acute myeloid leukemia (AML) is nearing completion. Dosing has advanced to the 350mg cohort, a dose level that greatly exceeds the 100mg dose approved for anti-infective use and is well within the range of doses that have demonstrated anti-cancer activity in published preclinical studies. Patient recruitment has been slowed by the submission of a protocol amendment.

The cost of this study has been covered by the academic sponsor. As the exclusive licensee of this technology, the company continues to monitor the progress of the trial and anticipates its completion in 2014. Following a thorough evaluation of the clinical data and the program’s commercial potential the company will decide on an appropriate path forward.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SCT Changes its Name to Trillium Therapeutics Inc.
Company has filed articles of amalgamation to merge with Trillium Therapeutics.
Tuesday, June 03, 2014
SCT to Provide Update on CD47 Program at the 2014 AACR Annual Meeting
Announcing a key difference between SIRPaFc and other CD47-blocking agents.
Friday, April 04, 2014
Stem Cell Therapeutics Strengthens its Board of Directors
Adds US industry veterans with broad financial and clinical expertise.
Tuesday, March 11, 2014
Stem Cell Therapeutics Announces Resignation of Director
Mr. David Allan has resigned from Company’s board of directors.
Thursday, January 30, 2014
Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman
Dr. Stiller has been a member of the Board since July 2011 and served as Lead Director and Chair of the Governance and Nominating Committee.
Thursday, January 30, 2014
Stem Cell Therapeutics Completes $33 Million Private Placement
Financing proceeds used to advance the Company’s CD47 cancer stem cell program.
Friday, December 20, 2013
Stem Cell Therapeutics Appoints Dr. Robert Kirkman to its Board of Directors
Provides update on $33 million offering.
Wednesday, December 18, 2013
Stem Cell Therapeutics Receives U.S. Orphan Drug Designation
Company receives drug designation for the use of tigecycline to treat AML.
Friday, November 01, 2013
Stem Cell Therapeutics Acquires Complementary Antibody Program
The company has entered into an option agreement to exclusively license worldwide rights to a panel of fully human monoclonal antibodies targeting the SIRPa protein (CD172a).
Thursday, October 17, 2013
Stem Cell Therapeutics Advances CD47 Antagonist Program into Ind-Enabling Phase
Stem Cell Therapeutics Corp. announced that it has advanced its CD47 antagonist program into an Investigational New Drug (IND) enabling phase.
Monday, September 09, 2013
SCT Acquires an Exclusive Option to License Prostate Cancer Stem Cell Assets
Collaboration with internationally renowned prostate cancer research group.
Monday, August 12, 2013
Stem Cell Therapeutics Acquires an Exclusive Option to License Prostate Cancer Stem Cell Assets
Collaboration with internationally renowned prostate cancer research group.
Monday, August 12, 2013
SCT Licenses Exclusive Rights to Clinical Cancer Stem Cell Program
Corporate refocusing mission completed.
Friday, April 19, 2013
SCT Announces Joint-Venture Agreement with Reneu and Nexgen
Company to move the combined technologies into clinical trials with a target of clinical initiation in 2014.
Wednesday, February 20, 2013
SCT Announces Agreement with Trillium for Merger
Continuing Stem Cell Therapeutics' commitment to expansion.
Wednesday, February 06, 2013
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!